NATCO Pharma Limited announces the launch of additional strengths for the generic version of Revlimid® (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.
With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
Revlimid® is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb Company.
